Linezolid 

Linezolid is a bacteriostatic oxazolidinone antibiotic effective against resistant Gram-positive organisms. It is particularly useful in MRSA pneumonia and VRE infections. Major concerns include myelosuppression, neuropathy, lactic acidosis, and serotonin syndrome.

 

  • Bacteriostatic against staphylococci and enterococci
  • Bactericidal against streptococci
  • No cross-resistance with other protein synthesis inhibitors

Resistance develops via:

  • Mutation in 23S rRNA
  • cfr gene–mediated methylation

 

1. Antimicrobial Spectrum

Excellent Coverage

✔ MRSA
✔ VRSA
✔ VRE (E. faecium > E. faecalis)
✔ Penicillin-resistant Streptococcus pneumoniae
✔ Streptococcus pyogenes
✔ Listeria

No Activity Against

✖ Gram-negative bacilli
✖ Pseudomonas
✖ Acinetobacter
✖ Anaerobes (limited)

 

2. Pharmacokinetics 

Bioavailability

  • 100% oral bioavailability
  • IV and oral doses are interchangeable

Distribution

  • Excellent lung penetration
  • Good CSF penetration
  • High epithelial lining fluid levels
  • Good bone penetration

 

3.Clinical Indications 

A. MRSA Pneumonia

As per Infectious Diseases Society of America (IDSA) guidelines:

  • Linezolid is preferred over vancomycin for MRSA pneumonia in some cases because:
    • Better lung penetration
    • No nephrotoxicity
    • No need for TDM

 

B. VRE Infections

  • Drug of choice for VRE bacteremia
  • Especially E. faecium

 

C. Skin & Soft Tissue Infections

  • Complicated SSTI due to MRSA

 

D. ICU Sepsis due to Resistant Gram-positives

Useful in:

  • Catheter-related bloodstream infections
  • Post-neurosurgical infections
  • Prosthetic infections

 

4. Linezolid vs Vancomycin 

Feature

Linezolid

Vancomycin

Oral bioavailability

100%

None

Lung penetration

Excellent

Moderate

Nephrotoxicity

No

Yes

TDM required

No

Yes

Bactericidal

Static

Cidal

Myelosuppression

Yes

No

 

5. Adverse Effects 

 Myelosuppression (Most Important)

  • Thrombocytopenia (most common)
  • Anemia
  • Leukopenia

 

 Peripheral Neuropathy

  • With prolonged therapy (>28 days)
  • Often irreversible

 

 Optic Neuropathy

  • Blurred vision
  • Color vision defects

 

 Lactic Acidosis

Due to mitochondrial protein synthesis inhibition.

Mechanism:

  • Mitochondrial ribosomes resemble bacterial ribosomes
  • Linezolid impairs oxidative phosphorylation

 

 Serotonin Syndrome 

Linezolid is a weak MAO inhibitor.

Risk when combined with:

  • SSRIs
  • SNRIs
  • TCAs
  • Tramadol
  • Meperidine

Clinical features:

  • Hyperthermia
  • Clonus
  • Hyperreflexia
  • Autonomic instability

 

 

Does Renal Failure Increase Toxicity?

Yes.

Although no dose adjustment is required:

  • Metabolites accumulate
  • Higher risk of thrombocytopenia

 

 

 6.Resistance Mechanisms

  1. 23S rRNA mutation
  2. cfr methyltransferase gene
  3. Efflux pumps

Emerging resistance seen globally.